Timing clarification: Zimmer Biomet scheduled its Q2 release for Wednesday, August 5, 2026, at 6:30 a.m. ET, followed by the earnings call at 8:30 a.m. ET. Thus, the announced reporting date is August 5—not tomorrow, August 6. (investor.zimmerbiomet.com)
| Metric | Q2 2026 expectation | Q2 2025 actual | Implied change |
|---|---|---|---|
| Revenue | ~$2.13B | $2.077B | ~+2.5% |
| Adjusted EPS | ~$2.01 | $2.07 | ~-3% |
| Adjusted operating margin | ~25.8% indicated | 27.8% | ~-200 bps |
Published consensus is approximately $2.13 billion of revenue and $2.01 of adjusted EPS, although estimate aggregators vary slightly. (benzinga.com)
Zimmer Biomet entered the quarter with full-year guidance for:
Q1 organic constant-currency growth was 2.9%, while adjusted EPS of $2.09 benefited by roughly $0.20 from tariff-related items. Management raised annual EPS guidance by $0.10 but left revenue guidance unchanged. (investor.zimmerbiomet.com)
This report is less about whether ZBH beats EPS by a few cents and more about whether its U.S. sales-force transformation is producing better underlying implant growth without creating excessive disruption.
Management is shifting representatives toward dedicated, specialized coverage and expects the project to run through the end of 2027. At the end of Q1:
Those operational indicators were encouraging, but Q1 U.S. knee growth of only 2.2% remained below the approximately 4%–4.5% reconstructive market growth rate cited by management. Investors will want evidence that the transition is now improving reported sales—not merely internal productivity statistics.
Knees are the most important swing factor. Q1 growth was constrained by:
Partial knees were a bright spot, with Oxford Partial Cementless sales rising more than 20%, but that was not enough to produce market-level growth for the overall U.S. knee franchise.
A credible Q2 result should show U.S. knee growth moving above Q1’s 2.2%, accompanied by evidence that ROSA placements and new account conversions are pulling through implant utilization. Another materially below-market quarter would raise doubts about management’s expectation for better second-half performance.
U.S. hips grew 5% organically in Q1, supported by the Z1 stem, OrthoGrid navigation and HAMMR impactor. Z1 already represented almost 40% of U.S. hip stems, suggesting that the company’s “hip triple-play” strategy has real momentum.
Technology and Data, Bone Cement and Surgical grew 11.7% organically in Q1, with underlying robotics growth closer to 30%. The comparison is easier in Q2: the category declined 2.2% organically in Q2 2025.
Investors should distinguish between:
Strong ROSA or TMINI placements are positive, but they become much more valuable if management can quantify subsequent knee and hip conversion.
Paragon 28 is central to ZBH’s diversification beyond large joints. Management said the foot-and-ankle business was nearly back to double-digit growth in Q1 and had entered Q2 growing in the teens.
That creates a relatively high bar. Investors should look for:
Because the acquisition closed in April 2025, most of Paragon’s growth is now entering the organic comparison. That makes the reported-versus-organic bridge less flattering but gives investors a cleaner look at the acquired business’s underlying performance.
Q1 international organic growth was 2.5%, affected by distributor changes in China, Europe, the Middle East and other emerging markets. Management expected international growth to improve toward the mid-single digits during the second half.
Q2 does not necessarily need to reach that level, but investors should expect:
A further slowdown would make the second-half acceleration embedded in management’s commentary harder to achieve.
Management explicitly guided Q2 adjusted operating margin to decline approximately 200 basis points year over year, implying roughly 25.8% versus 27.8% in Q2 2025.
The decline reflects:
The relevant question is therefore not whether margins decline, but whether the decline is contained and productive.
A margin near or above 25.8%, paired with improving implant growth, would support the argument that 2026 is a deliberate investment year. A weaker margin with no improvement in knees would suggest ZBH is absorbing the cost of the transition before receiving the revenue benefit.
Management previously indicated that Q3 operating margin could decline another approximately 50 basis points sequentially from Q2. Any change to that cadence will be important for second-half EPS estimates.
The current adjusted EPS range of $8.40–$8.55 has a midpoint of $8.48, almost exactly in line with published full-year consensus. That leaves little room for a merely mechanical guidance increase.
A constructive update would include some combination of:
After Q1, ZBH increased its anticipated 2026 share repurchases from $750 million to as much as $1 billion. That should support EPS, but investors will likely place more value on an operating-driven raise than on one primarily caused by a lower share count. (investor.zimmerbiomet.com)
This is the first earnings cycle following Suketu Upadhyay’s departure and Paul Stellato’s appointment as interim CFO. Investors will evaluate the continuity of financial communication, particularly around:
ZBH ended Q1 with approximately $7.05 billion of net debt, so the decision to expand repurchases increases the importance of consistent cash generation.
Management had expected:
Investors should listen for any change in submission timing, FDA interaction or commercial-launch preparation. The product is strategically important, but additional investment could pressure near-term margins before contributing meaningful revenue.
This would suggest that the commercial transformation is working sooner than expected and that 2026 represents the earnings trough.
This would be adequate, but management commentary on Q3 and the second half would determine the stock reaction.
That outcome would intensify concerns that the sales-force transition is more disruptive and expensive than management anticipated.
The key KPI is underlying U.S. knee acceleration, not headline EPS. ZBH has already established that hips, robotics and recent acquisitions can grow. What remains unproven is whether the commercial reorganization can close the company’s large-joint growth gap while keeping margin pressure temporary.
A small consensus beat with unchanged guidance may not be sufficient. The stronger signal would be:
If those elements are present, investors can look past a year-over-year EPS decline in Q2. If they are absent, the strategic promise of the robotics portfolio and sales-force overhaul will remain pushed further into the future.